Cargando…

Residual Beta Cell Function in Newly Diagnosed Type 1 Diabetes after Treatment with Atorvastatin: The Randomized DIATOR Trial

BACKGROUND: Recent evidence suggests that the lipid-lowering agent atorvastatin is also a potent immunomodulator. The aim of this study was to investigate the possible effect of atorvastatin on the decline of residual beta cell function in recent-onset type 1 diabetes. METHODS AND FINDINGS: The rand...

Descripción completa

Detalles Bibliográficos
Autores principales:	Martin, Stephan, Herder, Christian, Schloot, Nanette C., Koenig, Wolfgang, Heise, Tim, Heinemann, Lutz, Kolb, Hubert
Formato:	Texto
Lenguaje:	English
Publicado:	Public Library of Science 2011
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3055882/ https://www.ncbi.nlm.nih.gov/pubmed/21412424 http://dx.doi.org/10.1371/journal.pone.0017554

Ejemplares similares

Improved Preservation of Residual Beta Cell Function by Atorvastatin in Patients with Recent Onset Type 1 Diabetes and High CRP Levels (DIATOR Trial)
por: Strom, Alexander, et al.
Publicado: (2012)

The Systemic Immune Network in Recent Onset Type 1 Diabetes: Central Role of Interleukin-1 Receptor Antagonist (DIATOR Trial)
por: Kolb, Hubert, et al.
Publicado: (2013)

Ketone bodies: from enemy to friend and guardian angel
por: Kolb, Hubert, et al.
Publicado: (2021)

Elevated Levels of the Anti-Inflammatory Interleukin-1 Receptor Antagonist Precede the Onset of Type 2 Diabetes: The Whitehall II Study
por: Herder, Christian, et al.
Publicado: (2009)

Digital Diabetes Management: A Literature Review of Smart Insulin Pens
por: Heinemann, Lutz, et al.
Publicado: (2021)

COVID-19-Lockdown hat die akute Inzidenz des Typ-1-Diabetes nicht beeinflusst
por: Schloot, Nanette
Publicado: (2020)

High affinity binding of hydrophobic and autoantigenic regions of proinsulin to the 70 kDa chaperone DnaK
por: Burkart, Volker, et al.
Publicado: (2010)

Atorvastatin 10 mg plus ezetimibe versus titration to atorvastatin 40 mg: attainment of European and Canadian guideline lipid targets in high-risk subjects ≥65 years
por: Constance, Christian, et al.
Publicado: (2014)

Atorvastatin added to interferon beta for relapsing multiple sclerosis: a randomized controlled trial
por: Kamm, Christian Philipp, et al.
Publicado: (2012)

DSMM XI study: dose definition for intravenous cyclophosphamide in combination with bortezomib/dexamethasone for remission induction in patients with newly diagnosed myeloma
por: Kropff, Martin, et al.
Publicado: (2009)

Insulin resistance and beta‐cell dysfunction in newly diagnosed type 2 diabetes: Expression, aggregation and predominance. Verona Newly Diagnosed Type 2 Diabetes Study 10
por: Bonora, Enzo, et al.
Publicado: (2022)

SWiss Atorvastatin and Interferon Beta-1b Trial In Multiple Sclerosis (SWABIMS) - rationale, design and methodology
por: Kamm, Christian P, et al.
Publicado: (2009)

The effect of atorvastatin on pancreatic beta cell requirement in women with polycystic ovary syndrome
por: Sathyapalan, Thozhukat, et al.
Publicado: (2017)

The comparative efficacy of ezetimibe added to atorvastatin 10 mg versus uptitration to atorvastatin 40 mg in subgroups of patients aged 65 to 74 years or greater than or equal to 75 years
por: Ben-Yehuda, Ori, et al.
Publicado: (2011)

The Beta-Cell Function and Glucose Profile of Newly Diagnosed Acromegalic Patients with Normal Glucose Tolerance
por: Sun, Quanya, et al.
Publicado: (2021)

Associations of insulin resistance and beta-cell function with abnormal lipid profile in newly diagnosed diabetes
por: Tang, Xiaohan, et al.
Publicado: (2022)

Mechanisms Underlying the Onset of Oral Lipid–Induced Skeletal Muscle Insulin Resistance in Humans
por: Nowotny, Bettina, et al.
Publicado: (2013)

Comparison between newly diagnosed hypertension in diabetes and newly diagnosed diabetes in hypertension
por: Liu, Chang-Yuan, et al.
Publicado: (2019)

Sustained minimal residual disease negativity in newly diagnosed multiple myeloma and the impact of daratumumab in MAIA and ALCYONE
por: San-Miguel, Jesus, et al.
Publicado: (2022)

Incidence of newly diagnosed diabetes after Covid-19
por: Rathmann, Wolfgang, et al.
Publicado: (2022)

CACNA1E Variants Affect Beta Cell Function in Patients with Newly Diagnosed Type 2 Diabetes. The Verona Newly Diagnosed Type 2 Diabetes Study (VNDS) 3
por: Trombetta, Maddalena, et al.
Publicado: (2012)

Austria-based real-world data on bevacizumab in newly diagnosed epithelial ovarian cancer
por: Tsibulak, Irina, et al.
Publicado: (2022)

Higher-dose venetoclax with measurable residual disease-guided azacitidine discontinuation in newly diagnosed acute myeloid leukemia
por: Gutman, Jonathan A., et al.
Publicado: (2023)

Avelumab in newly diagnosed glioblastoma
por: Jacques, Francois H, et al.
Publicado: (2021)

Short-time intensive insulin therapy upregulates 3 beta- and 17 beta-hydroxysteroid dehydrogenase levels in men with newly diagnosed T2DM
por: Hu, Yun, et al.
Publicado: (2022)

Role of the Wearable Defibrillator in Newly Diagnosed Heart Failure
por: Duncker, David, et al.
Publicado: (2018)

Sample Size Requirements for Studies of Treatment Effects on Beta-Cell Function in Newly Diagnosed Type 1 Diabetes
por: Lachin, John M., et al.
Publicado: (2011)

Systemic TNFα correlates with residual β-cell function in children and adolescents newly diagnosed with type 1 diabetes
por: Overgaard, Anne Julie, et al.
Publicado: (2020)

Response rates and minimal residual disease outcomes as potential surrogates for progression-free survival in newly diagnosed multiple myeloma
por: Daniele, Patrick, et al.
Publicado: (2022)

Short overview on the current standard of treatment in newly diagnosed multiple myeloma
por: Willenbacher, Ella, et al.
Publicado: (2018)

Atorvastatin Added to Interferon Beta for Relapsing Multiple Sclerosis: 12-Month Treatment Extension of the Randomized Multicenter SWABIMS Trial
por: Kamm, Christian P., et al.
Publicado: (2014)

Cilengitide in newly diagnosed glioblastoma: biomarker expression and outcome
por: Weller, Michael, et al.
Publicado: (2016)

Atorvastatin-induced pancreatitis
por: Prajapati, Samir, et al.
Publicado: (2010)

Atorvastatin (Lipitor) by MCR
por: Zarganes-Tzitzikas, Tryfon, et al.
Publicado: (2019)

Newly Diagnosed Acute Promyelocytic Leukemia
por: Avvisati, Giuseppe
Publicado: (2011)

Therapy of newly diagnosed follicular lymphoma
por: Westin, Jason R., et al.
Publicado: (2012)

Advances in the treatment of newly diagnosed glioblastoma
por: Theeler, Brett J., et al.
Publicado: (2015)

A Review of Newly Diagnosed Glioblastoma
por: Oronsky, Bryan, et al.
Publicado: (2021)

Newly Diagnosed Glioblastoma in Elderly Patients
por: Yuen, Carlen A., et al.
Publicado: (2022)

Newly Diagnosed IDH-Wildtype Glioblastoma and Temporal Muscle Thickness: A Multicenter Analysis
por: Wende, Tim, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_mcac4i9acrgig5ph934muc0h9o